Odronextamab
Detailed article on Odronextamab, a bispecific monoclonal antibody
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Odronextamab is a bispecific monoclonal antibody designed for the treatment of certain types of B-cell non-Hodgkin lymphoma. It is currently under investigation in clinical trials and has shown promise in targeting and eliminating cancerous B-cells by engaging the body's own immune system.
Mechanism of Action[edit | edit source]
Odronextamab is engineered to bind simultaneously to CD20 on B-cells and CD3 on T-cells. This dual binding brings T-cells into close proximity with B-cells, facilitating the T-cell-mediated killing of the B-cells. The engagement of CD3 on T-cells activates them, leading to the release of cytotoxic granules and cytokines that induce apoptosis in the target B-cells.
Clinical Development[edit | edit source]
Odronextamab is being developed by Regeneron Pharmaceuticals. It is currently in phase 2 clinical trials for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Early clinical data have demonstrated significant anti-tumor activity, with manageable safety profiles.
Pharmacokinetics[edit | edit source]
The pharmacokinetics of odronextamab involve its distribution, metabolism, and excretion. As a monoclonal antibody, it is expected to have a long half-life, allowing for less frequent dosing. The drug is administered intravenously, and its clearance is primarily through proteolytic catabolism.
Adverse Effects[edit | edit source]
Common adverse effects observed in clinical trials include cytokine release syndrome (CRS), which is a common side effect of T-cell engaging therapies. Other side effects may include infusion-related reactions, fatigue, and hematological toxicities.
Regulatory Status[edit | edit source]
As of the latest update, odronextamab has not yet received approval from major regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It remains an investigational drug.
Research and Future Directions[edit | edit source]
Ongoing research is focused on optimizing the dosing regimen and minimizing adverse effects. Combination therapies with other agents are also being explored to enhance efficacy and overcome resistance mechanisms.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
